Medical treatment of diabetic retinopathy with somatostatin analogues

Stela S. Palii, Sergio Caballero, Gideon Shapiro, Maria B. Grant

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2007

Fingerprint

Diabetic Retinopathy
Somatostatin
Octreotide
Laser Therapy
Pharmacology
Retinal Neovascularization
Retinal Vessels
Light Coagulation
Vision Disorders
Therapeutic Uses
Therapeutics
Clinical Trials
Pathology
Research

Keywords

  • Diabetic retinopathy
  • Neovascularisation
  • Octreotide
  • Somatostatin analogues
  • Somatostatin receptor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Medical treatment of diabetic retinopathy with somatostatin analogues. / Palii, Stela S.; Caballero, Sergio; Shapiro, Gideon; Grant, Maria B.

In: Expert Opinion on Investigational Drugs, Vol. 16, No. 1, 01.01.2007, p. 73-82.

Research output: Contribution to journalReview article

Palii, Stela S. ; Caballero, Sergio ; Shapiro, Gideon ; Grant, Maria B. / Medical treatment of diabetic retinopathy with somatostatin analogues. In: Expert Opinion on Investigational Drugs. 2007 ; Vol. 16, No. 1. pp. 73-82.
@article{90a67fe3213442ce90b751ae6ce3abd0,
title = "Medical treatment of diabetic retinopathy with somatostatin analogues",
abstract = "Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.",
keywords = "Diabetic retinopathy, Neovascularisation, Octreotide, Somatostatin analogues, Somatostatin receptor",
author = "Palii, {Stela S.} and Sergio Caballero and Gideon Shapiro and Grant, {Maria B.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1517/13543784.16.1.73",
language = "English (US)",
volume = "16",
pages = "73--82",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
number = "1",

}

TY - JOUR

T1 - Medical treatment of diabetic retinopathy with somatostatin analogues

AU - Palii, Stela S.

AU - Caballero, Sergio

AU - Shapiro, Gideon

AU - Grant, Maria B.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.

AB - Traditional management strategies for retinal neovascularisation accompanying proliferative diabetic retinopathy include photocoagulation laser therapy. The development of preventative pharmacological treatments aimed at replacing or delaying this acute intervention has been an active research area and somatostatin analogues have shown promise in reducing the progression of retinal vascular pathologies. This review summarises the present knowledge on the molecular and cellular mechanisms of neo-vascularisation, and the rationale for the therapeutic use of somatostatin analogues as well as the results of two key recent clinical trials using octreotide. The potential use of octreotide and other somatostatin analogues in reducing the risk of severe visual impairment in proliferative diabetic retinopathy is discussed and pharmacological treatment regimens are proposed as an additional strategy or a less invasive alternative to laser therapy.

KW - Diabetic retinopathy

KW - Neovascularisation

KW - Octreotide

KW - Somatostatin analogues

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=33845700582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845700582&partnerID=8YFLogxK

U2 - 10.1517/13543784.16.1.73

DO - 10.1517/13543784.16.1.73

M3 - Review article

C2 - 17155855

AN - SCOPUS:33845700582

VL - 16

SP - 73

EP - 82

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 1

ER -